Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) EVP Brian Baranick sold 929 shares of the firm’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $70.00, for a total value of $65,030.00. Following the sale, the executive vice president now directly owns 13,687 shares of the company’s stock, valued at approximately $958,090. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Exact Sciences Stock Up 2.3 %
Shares of NASDAQ:EXAS traded up $1.62 during trading on Thursday, hitting $70.83. 2,583,414 shares of the company were exchanged, compared to its average volume of 2,664,718. The firm’s 50 day moving average price is $56.33 and its 200-day moving average price is $55.68. Exact Sciences Co. has a 12-month low of $40.62 and a 12-month high of $79.62. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.17 and a quick ratio of 1.98. The stock has a market capitalization of $13.07 billion, a P/E ratio of -54.16 and a beta of 1.26.
Exact Sciences (NASDAQ:EXAS – Get Free Report) last released its quarterly earnings data on Wednesday, July 31st. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.28. Exact Sciences had a negative net margin of 6.70% and a negative return on equity of 4.97%. The company had revenue of $699.26 million during the quarter, compared to the consensus estimate of $690.02 million. During the same quarter in the prior year, the firm posted ($0.45) earnings per share. Exact Sciences’s revenue for the quarter was up 12.4% on a year-over-year basis. On average, research analysts predict that Exact Sciences Co. will post -0.87 earnings per share for the current fiscal year.
Analyst Ratings Changes
Read Our Latest Stock Report on EXAS
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the company. Itau Unibanco Holding S.A. acquired a new stake in shares of Exact Sciences in the second quarter valued at approximately $29,000. Benjamin F. Edwards & Company Inc. increased its stake in Exact Sciences by 65.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 452 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 179 shares during the period. Able Wealth Management LLC purchased a new stake in shares of Exact Sciences in the fourth quarter valued at about $45,000. EverSource Wealth Advisors LLC boosted its stake in shares of Exact Sciences by 92.4% during the first quarter. EverSource Wealth Advisors LLC now owns 708 shares of the medical research company’s stock worth $49,000 after buying an additional 340 shares during the period. Finally, Fortitude Family Office LLC purchased a new position in shares of Exact Sciences during the first quarter worth about $55,000. Hedge funds and other institutional investors own 88.82% of the company’s stock.
Exact Sciences Company Profile
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Featured Stories
- Five stocks we like better than Exact Sciences
- Why Invest in 5G? How to Invest in 5G Stocks
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- How Can Investors Benefit From After-Hours Trading
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- How to Invest in Biotech Stocks
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.